Liver biopsy
β Scribed by Don C. Rockey; Stephen H. Caldwell; Zachary D. Goodman; Rendon C. Nelson; Alastair D. Smith
- Publisher
- John Wiley and Sons
- Year
- 2008
- Tongue
- English
- Weight
- 417 KB
- Volume
- 49
- Category
- Article
- ISSN
- 0270-9139
No coin nor oath required. For personal study only.
β¦ Synopsis
This position paper has been approved by the AASLD and represents the position of the association.
Preamble
These recommendations provide a data-supported approach. They are based on the following: (1) formal review and analysis of the recently published world literature on the topic; (2) American College of Physicians Manual for Assessing Health Practices and Designing Practice Guidelines 1 ; (3) guideline policies, including the AASLD Policy on the Development and Use of Practice Guidelines and the American Gastroenterological Association Policy Statement on Guidelines 2 ; and (4) the experience of the authors in the specified topic.
Intended for use by physicians, these recommendations suggest preferred approaches to the diagnostic, therapeutic, and preventive aspects of care. They are intended to be flexible, in contrast to standards of care, which are inflexible policies to be followed in every case. Specific recommendations are based on relevant published information. To more fully characterize the quality of evidence supporting recommendations, the Practice Guidelines Committee of the AASLD requires a Class (reflecting benefit versus risk) and Level (assessing strength or certainty) of Evidence to be assigned and reported with each recommendation (Table , adapted from the American College of Cardiology and the American Heart Association Practice Guidelines 3 ).
π SIMILAR VOLUMES
I can hardly share the passionate enthusiasm of Breuhahn et al. for the ''dramatic'' improvements in understanding of molecular pathogenesis of hepatocellular carcinoma (HCC) and the claim for ''further rationally designed clinical trials based on molecular evidence''. 1 Among the causes of HCC, the
There is controversy about the frequency of and risk factors rate of 0.2% to 1.8%. 1,2,3,4,5 Most complications are caused for infectious complications of percutaneous liver biopsy in by either lung perforation or bleeding from lacerated interliver transplant recipients. The aim of this study was to